Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.53 |
| ▸ | GRM5 | P41594 | 10/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26130710 | 0.86 | PDK4 (0.55) | PDK4GRM1GRM5HTR6NAMPT | |
| SCHEMBL1806361 | 0.84 | PDK4 (0.61) | PDK4GRM1GRM5HTR6NAMPT | |
| SCHEMBL29744751 | 0.83 | PDK4 (0.54) | PDK4GRM1GRM5HTR6NAMPT | |
| SCHEMBL6402391 | 0.83 | PDK4 (0.54) | PDK4GRM1GRM5HTR6NAMPT | |
| SCHEMBL30061046 | 0.82 | PDK4 (0.68) | PDK4GRM1GRM5HTR6NAMPT | |
| SCHEMBL83700 | 0.82 | PDK4 (0.68) | PDK4GRM1GRM5HTR6NAMPT | |
| SCHEMBL21245869 | 0.82 | PDK4 (0.53) | PDK4GRM1GRM5HTR6NAMPT | |
| SCHEMBL29405638 | 0.82 | PDK4 (0.53) | PDK4GRM1GRM5HTR6NAMPT | |
| SCHEMBL29197065 | 0.81 | PDK4 (0.53) | PDK4GRM1GRM5HTR6NAMPT | |
| SCHEMBL17393489 | 0.81 | PDK4 (0.53) | PDK4GRM1GRM5HTR6NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117940133-A | Therapeutic agents for degradation of mutant BRAF | C4医药公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022192162-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2022-09-15 | — | — | WO | disclosed |